Isomorphic Labs

Isomorphic Labs is not a venture investor; it is an Alphabet-owned drug discovery company spun out of DeepMind in 2021 to apply AI, including AlphaFold-derived techniques, to small-molecule design and structural biology for pharmaceutical development. The organization partners with pharma companies on drug discovery programs and pursues internal pipeline development rather than allocating capital into other startups. Founders pitching Isomorphic Labs as an investor should reset expectations: this is a counterparty for partnerships, scientific collaborations, or potential acquisitions, not a source of equity capital. Healthcare and AI focus are total and concentrated in computational drug discovery, molecular dynamics, and structural prediction. The most useful entry path for a founder is not a fundraising pitch but a partnership or business development conversation, particularly if the founder’s company has differentiated chemistry, target biology, or experimental platforms that complement Isomorphic’s computational engine. The introduction path is warm referral through DeepMind, Google, or pharma business development executives, or direct outreach through the Isomorphic Labs website business development channel. LinkedIn outreach to a senior business development or partnerships leader with a clear scientific value proposition is a reasonable secondary option. Founders looking for capital should look elsewhere; founders looking for a deeply technical partner on a specific drug discovery problem may find a meaningful relationship. Expect long, scientifically rigorous evaluation cycles and partnership economics rather than equity terms.